Search alternatives:
ppm decrease » _ decrease (Expand Search), nn decrease (Expand Search), pa decreased (Expand Search)
nm decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
ppm decrease » _ decrease (Expand Search), nn decrease (Expand Search), pa decreased (Expand Search)
nm decrease » nn decrease (Expand Search), _ decrease (Expand Search), we decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
1641
-
1642
Inhibition of SHP-2 activity decreases <i>C</i>. <i>parvum</i> infectivity.
Published 2015“…<p>A) Dose-dependent decrease of Infections per field of view (y-axis) after treatment of FHs 74 Int cells with increasing concentrations of the SHP-2-specific inhibitor, SHP-2 PTPase Inhibitor. …”
-
1643
-
1644
-
1645
-
1646
-
1647
Decreased Aβ42 halo overlaps with the decreased incidence of DNs in FO treated mice.
Published 2019“…(E-H) In the FO-treated 5xFAD animals the decreased surface of the Aβ halo overlaps with the decreased incidence of swollen, dystrophic neurites.…”
-
1648
Inhibition of MRP1 significantly decreases basal and apoptotic GSH efflux.
Published 2012“…GSH release from MRP1-silenced ARPE-19 cells incubated with 150 µM H<sub>2</sub>O<sub>2</sub> for 5 h in serum free medium. A significant decrease (P<0.001 vs scrambled control) in GSH release was observed in 5 h. …”
-
1649
-
1650
Nilotinib decreases the <i>in vitro</i> tumorigenicity of HEI-193 cells.
Published 2013“…(C) The mean maximal colony diameter was decreased by nilotinib at ≥3 µM in PDGF-BB media, and at ≥5 µM in GM. …”
-
1651
-
1652
-
1653
-
1654
-
1655
-
1656
The number of behavioral arrests in DKO mice decreased following systemic atropine.
Published 2011“…<p>(A) Mean (± SEM) time per mouse spent in full behavioral arrests are plotted in 30 min bins across the entire recording period following IP injections of saline (open symbols) and atropine (0.5 mg/kg; filled symbols). …”
-
1657
-
1658
The estrogen receptor-α agonist PPT decreases cardiac myofilament activation.
Published 2013“…<p>Myocardium was treated with the estrogen receptor-α agonist PPT (100 nM) for 1 (A) (N = 9), 2.5 (B) (N = 9), or 5 min (C) (N = 22). …”
-
1659
-
1660